AGP Executive Report
Last update: 34 minutes agoCancer Watch: The CONVERGE phase 2 trial reports strong early results for JNJ-1900 (NBTXR3) in stage III unresectable NSCLC, with 85.7% overall response and 100% disease control after chemoradiotherapy plus durvalumab. Breast Cancer Momentum: The FDA approved datopotamab deruxtecan (dato-DXd) for first-line metastatic triple-negative breast cancer in patients who can’t get PD-1/PD-L1 therapy, while sacituzumab tirumotecan (sacituzumab tirumotecan) hit a key PFS endpoint in OptiTROP-Breast03. Bladder Cancer: CHMP gave a positive opinion for a pembrolizumab-containing combo as perioperative treatment for cisplatin-ineligible resectable muscle-invasive bladder cancer. Public Health: WHO upgraded Ebola in DRC to “very high” risk nationally, and Europe is also watching the cruise-ship hantavirus cluster. Heat & Food Safety: Western Europe braces for an early heatwave, and new research flags cancer-linked chemicals hidden in everyday foods. Policy & Lifestyle: Belgium’s vape-flavor ban is set to take effect in 2028, and Ireland is considering food price caps for “varied, balanced” diets.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
